Drug Discovery & Development
Top PE investments in biotools in 2021
2021 was an especially active year for private equity (PE) firms. According to PitchBook, the number of deals surged over 51% last year to top 8,600. Among the beneficiaries of the 29% increase in deals were biotool firms, which supply laboratory instrumentation and aftermarket supplies for the analysis of genes, cells, and proteins (excluding in vitro diagnostics tools). Read More
Kevin DeGeeter in 5 questions, part of Biotech Finance Month 2022
Scientific innovation is happening at an ultrasonic rate these days, but what does this mean for cancer patients and their treatment options? This was the topic of "Outsmarting Cancer: Next Generation Therapies," a session at Biotech Showcase 2022. Kevin DeGeeter, managing director and senior analyst, biotechnology and diagnostics, at Oppenheimer, moderated the robust panel discussion and shared his insights with ScienceBoard as part of Biotech Finance Month 2022. Read More
'Safe harbors' found for additions to human genome
A new way to find suitable places to make additions to the genome could give a boost to gene therapies. In a paper published January 24 in Cell Reports Methods, scientists describe an approach to find "safe harbors" in the genome that can receive new genes without causing unintended changes, such as promoting cancer. Read More
CAR T-cell therapy collaborations expand cancer treatment options
Considering the broad range of the causes of cancer and the heavy impact on patients, advanced and innovative treatments are essential to fighting it. One technology being explored for this purpose is CAR T-cell therapy, because it trains the body's immune system to specifically target cancerous cells, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Some healthcare institutions are collaborating with companies to develop such technologies, including Celularity, Lonza, and the Memorial Sloan Kettering Cancer Center. Read More
Roswell Biotechnologies demonstrates scalable molecular electronics chip
Roswell Biotechnologies and leading academic scientists have developed the first molecular electronics chip, realizing a 50-year-old goal of integrating single molecules into circuits to achieve the ultimate scaling limits of Moore's Law. Read More
Investors double down on AI drug development
Funding for artificial intelligence (AI) in drug development hit $4.1 billion in 2021, a 36% increase from the year before, according to Emersion Insights. The AI drug development industry has gained a lot of attention from investors, venture capital firms, and corporate investment funds in recent years. Read More
Resilience key to success during pandemic and beyond
It has been a challenging past couple of years for the world with the pandemic impacting seemingly every aspect of life. Companies that have remained agile and dedicated to problem-solving have been able to weather the storm more easily compared to those that lacked strong contingency plans, according to Bryan Katz, senior vice president and global head of solution development at Syneos Health, who moderated a panel discussion at Biotech Showcase 2022. Read More
BD innovation highlights new flow cytometry tech
A new study conducted by Becton Dickinson (BD) in collaboration with the European Molecular Biology Laboratory, which was published as the cover story of Science on January 20, profiles a BD innovation in flow cytometry that adds fluorescence imaging and image-based decisioning to sort individual cells at an exceptionally high speed. Read More
Targeted nanoparticle delivery provides boost for diabetes transplant
Delivering immunosuppressant treatment via targeted nanoparticles could open the door to a long-lasting cure for type 1 diabetes. Transplanting insulin-producing cells is a promising approach to treat the disease; however, it is plagued by issues of immune rejection. In a new study, published January 17 in Nature Nanotechnology, mice treated with a reengineered therapy could tolerate a transplant for much longer with fewer side effects. Read More
Developments in cell therapy boost potential for autoimmune disease treatments
Healthcare leaders are working together to change the therapeutic landscape for autoimmune diseases, which are often due to unknown causes, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Atara Biotherapeutics, Kyverna Therapeutics, and the National Institutes of Health are a few organizations that are dedicated to finding treatments for patients with limited options. Read More
Conferences
SLAS2022 International Conference & Exhibition
February 5-9
Boston, Massachusetts United States
HPLC 2022
June 18-23
San Diego, California United States
Science Briefs
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter